Ludwig Institute for Cancer Research Limited

Memorial Sloan Kettering Cancer Center

Institute of Molecular Biology and Genetics National Academy of Science of Ukraine

Sloan-Kettering Institute for Cancer Research

Institute for Molecular Biology and Genetics National Academy of Science of Ukraine

Institute of Molecular Biology and Genetics National Academy of Sciences of Ukraine

George Mark

Gerd J Ritter

Anne Murray

Kenneth O Lloyd

Ivan Tarasovich Gout

Ramziya Kiyamova

Valeriy Filonenko

Serhiy Souchelnytskiy

Beatrice Yin

Lloyd J Old

Con Panousis

Antony Wilks Burgess

Lloyd Old

Webster K Cavenee

Edouard Collins Nice

Christoph Renner

Achim Jungbluth

Terrance Grant Johns

Andrew Mark Scott

Peter Collins

Huei-Jen Su Huang

Viktorovich Filonenko

Terrance Grant Jonhs

Ivan Gout

Gerd Ritter

Elizabeth Stockert

The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy

Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

Specific binding proteins and uses thereof

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Membrane transporter NaPi2b (SCL34A2) epitope antibodies

Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Growing community of inventors

New York, NY, United States of America

George Mark